Gilead Sciences study data shows long-term efficacy of Stribild

Gilead Sciences has announced positive long-term efficacy and safety results from two pivotal phase III studies of its HIV therapy Stribild.

Data from Study 102 and Study 103 revealed that after three years of treatment, Stribild demonstrated comparable efficacy to two standard-of-care HIV regimens – Atripla in the first trial and a protease inhibitor-based regimen of ritonavir-boosted atazanavir plus Truvada in the second.

This long-term data, collated using treatment-naive patients, demonstrate the sustained efficacy, safety and tolerability profile of Stribild, in terms of its high and durable viral suppression.

Stribild contains four Gilead compounds – elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate – in a complete once-daily, single-tablet regimen. It has been approved for sale in both the US and EU.

Dr Jurgen Rockstroh, professor of medicine at the University of Bonn in Germany, said: "HIV has become a chronic disease that can be managed with lifelong therapy, increasing the need for convenient, once-daily treatment options that offer long-term efficacy and tolerability."

Earlier this month, the company announced that it will be bringing a phase III trial of its chronic lymphocytic leukaemia therapy idelalisib to an early conclusion, based on the positive results it has recorded thus far.